–Select one poster and one oral presentation that highlight the company’s new preclinical data on interferon-α Agonist Program——
SOUTH SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapies for serious viral diseases, today announced Preclinical and clinical data from its virology portfolio will be presented in two presentations at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting®taking place in Boston from November 10-14, 2023.
At the conference, a poster will share new preclinical data from the company’s interferon-alpha receptor (IFNAR) agonist program targeting chronic hepatitis B virus (HBV), which is currently undergoing lead optimization. In addition, oral presentations will focus on the first-generation core inhibitor velbicovir (VBR) combined with nucleos